STORM Therapeutics has joined forces with AlidaBio, a US-based company, to speed up the development of new cancer treatments that focus on changes in RNA, a crucial part of our cells. RNA changes can affect how cancer grows and spreads. The two companies will work together to better understand how a specific enzyme, called METTL3, influences cancer. STORM has a drug called STC-15 that blocks this enzyme, and they are testing it in early-stage clinical trials. AlidaBio has special tools to measure these RNA changes in patients’ samples. By studying these changes, the companies hope to link them to how well patients respond to the treatment. They also want to find out if certain RNA patterns can help predict which patients will benefit most from the drug. Eric Martin, from STORM, said that AlidaBio’s expertise will help them understand how the drug works in the body and improve outcomes for cancer patients. Gudrun Stengel, from AlidaBio, explained that their tools will help evaluate the drug’s effectiveness by studying RNA changes in patients. This partnership highlights the importance of understanding RNA changes in developing more precise and effective cancer treatments.